Cladribine administration has been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging.
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study / Petracca, M., Ruggieri, S., Barbuti, E., Ianniello, A., Fantozzi, R., Maniscalco, G.T., Andreone, V., Landi, D., Marfia, G.A., Di Gregorio, M., Iodice, R., Sinisi, L., Maida, E., Missione, R., Coppola, C., Bonavita, S., Borriello, G., Centonze, D., Lus, G., Pozzilli, C., et al.. - In: NEUROLOGY AND THERAPY. - ISSN 2193-8253. - 11:3(2022), pp. 1193-1208. [10.1007/s40120-022-00364-6]
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
Petracca, Maria;Ruggieri, Serena;Barbuti, Elena;Ianniello, Antonio;Borriello, Giovanna;Pozzilli, Carlo;
2022
Abstract
Cladribine administration has been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging.| File | Dimensione | Formato | |
|---|---|---|---|
|
s40120-022-00364-6.pdf
accesso aperto
Note: Petracca_Predictors of Cladribine Effectiveness_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
646.65 kB
Formato
Adobe PDF
|
646.65 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
